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of healthAbstract The present study aimed at systematically reviewing the role and extent
of patient-reported outcomes (PROs) usage within the package of scientific evidence
considered for marketing authorization (MA). All regulatory information published
by the European Medicines Agency (EMA) for products authorized between
January 2008 and December 2012 and appearing in the European Public
Assessment Report (EPAR) database was examined for efficacy endpoints. The end-
points here considered included: PROs, clinician reported outcomes (CROs), and lab-
oratory reported outcomes (LROs). LROs were the most frequently reported
endpoints. Out of the 180 products here selected, 99 (55%), 67 (37%), and 30
(17%), respectively, used LROs, CROs and PROs as primary endpoints (PEs). PROs
as any endpoints were used in 82 (46%) products. Out of these, PROs were docu-
mented as PE in 30 (37%), with 27 (33%) products having used PROs both as primary
and non-PEs. PRO usage was most frequently identified with nervous system and
antineoplastic agents. During the study period, the use of all the three types of end-
points appeared to be static. Both the regulatory bodies and the industry should
ensure complete and clear reporting of all endpoints used, including PROs, to
improve transparency.
ª 2015 Ministry of Health, Saudi Arabia. Published by Elsevier Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).1. Introduction
The European Public Assessment Report (EPAR)
made available by the European Medicines Agency
(EMA) contains the index pharmaceutical product
regulatory information [1,2]. It is published with
the aim of granting the marketing authorization
386 D. Bansal et al.(MA) for any new pharmaceutical, and it is publicly
accessible to allow satisfactory levels of trans-
parency in the decision-making process [2]. The
related scientific evidence is described in the sci-
entific discussion part (SDP) and the molecule phar-
macodynamics in the EPAR Summary of Product
Characteristics (SPC) section. The SPC contains
the information about both the clinical study end-
points and the health outcomes used during the
evaluation phase of the product [3].
The regulatory drug approval is based on a range
of clinical trial endpoints which are used to deter-
mine the biological activity, the clinical benefits,
and the molecule safety profile [4]. The tradition-
ally used endpoints include: the clinician-
reported outcomes (CROs; e.g., those observed
by the physician or which require an interpretation
by the physician, i.e., radiography results) [4,5];
and the laboratory reported outcomes (LROs;
e.g., objective measures performed by instru-
ments) [4,5]. Finally, the patient-reported out-
come(s) (PRO) is a generic term applicable to any
health-related data reported directly by the
patient without requiring an interpretation by the
physician. These data typically include: symptoms,
functional status, satisfaction with therapy, or
treatment adherence [5,6]. PRO measures extend
the range of patient outcomes that can be assessed
beyond the traditional measures of survival rates,
clinical efficacy and side effects. Thus, PROs allow
researchers to capture the patients perspectives
on a range of parameters, including: symptoms,
overall health status, and the impact of disease
and treatment on quality of life [7]. Health-
related quality of life (HRQoL) is a specific subset
of PROs defined as the patients subjective percep-
tion of the impact of disease and treatment(s) on
daily life, physical, psychological, social function-
ing and well-being [7].
Although CROs and LROs are valuable, they may
miss significant components of the patients experi-
ence. These endpoints are inadequate in conditions
such as pain, depression and fatigue, typically
requiring patients evaluation of their symptoms
and health status [8]. PROs are used particularly
for products used for treating chronic, disabling
and incurable conditions, the treatment of which
is administered with the purpose of improving both
symptomatology and HRQoL levels [9,10].
Arguably, PROs may be considered as primary
endpoints (PEs) in drug development for diseases
such as cancer, pain, migraine, and irritable bowel
syndrome. As non-PEs, PROs are also used in dis-
eases such as depression, insomnia, and asthma.
In rheumatoid arthritis and cancer, PROs are usedto assess the treatment benefits and tolerability
to better assess the medication impact on HRQoL.
PROs can also be used in clinical trials to assess
treatment satisfaction, compliance, and the care-
giver burden [7]. Finally, PROs are also included
in safety reporting, as discussed by the patient-
reported outcomes safety event reporting
(PROSPER) consortium [11]. Previous PRO usage
analyses have been relatively focused on drug
approvals [12]; labelling claims [5,13,14]; or single
assessment tools [15]. PRO measures have also
been examined in disease-specific contexts, includ-
ing cancer [16–18] and rheumatoid arthritis [19].
Concerns relating to HRQoL increased usage,
requirements of internal and external validation,
and terminology standardization led to the release
in 2006 of a reflection paper by the EMA [20]. This
paper has provided broad recommendations on
HRQoL usage in the context of already existing clin-
ical guidance documents.
Improvement of recovering and survival rates
remains the key target for drug development.
However, identifying a range of parameters that
can better describe the improvement levels in
terms of patients feelings, overall HRQoL, and/or
their overall functioning is an increasingly demand-
ing goal. One could argue that drugs with a similar
efficacy may present with different PRO levels,
hence, PROs may be seen as an important gauge
in the development of new treatment options
[21,22]. The present study aimed at systematically
reviewing the role and extent of PRO use within the
package of scientific evidence considered for mar-
keting authorization, as documented by the EPAR,
over a period of 5 years (2008–2012). This study
also aimed at exploring both the disease areas
and the types of PROs being used.
2. Materials and methods
2.1. Search strategy
A systematic comprehensive electronic and manual
search was performed herein for all the product-
level regulatory documents (EPAR) published by
EMA [23] from January 2008 to December 2012,
with a special emphasis given to PROs being used
in the regulatory process. The present analysis
reviewed the distribution of CRO/LRO/PRO as clin-
ical trial endpoints during the medicinal product
approval prior to marketing authorization.
2.2. Selection criteria
EPARs of all medicinal products registered with the
EMA were individually reviewed. The inclusion
Fig. 1 Endpoint combinations (N = 180). CRO: n = 54
(30.0%); LRO: n = 88 (48.9%); PRO: n = 25 (13.9%);
CRO + LRO: n = 8 (4.4%); CRO + PRO: n = 2 (1.1%);
PRO + LRO: n = 0 (0.0%); CRO + LRO + PRO: n = 3 (1.7%).
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whether approved or rejected, was registered with
the EMA during the study period; and (ii) availabil-
ity of objective documentation relating to efficacy
and tolerability endpoints. Exclusion criteria were
as follows: (i) the medicinal product was generic,
e.g., no clinical efficacy studies had been con-
ducted; (ii) the medicinal product had been
approved on the basis of bibliographic data or liter-
ature review only; and (iii) in the medicinal pro-
duct approval procedure, no endpoints were
mentioned. Products having the same EPAR but dif-
ferent authorization dates were not considered as
duplicates and hence were included in the present
review. For the standard definition of HRQoL and
PRO, the related EMA [20] and the latest Food
and Drug Administration (FDA) [24] guidance were
respectively used.
2.3. Data extraction
Two authors independently reviewed each EPAR
document to assess the appropriateness for inclu-
sion in the present analysis prior to data extrac-
tion. The information regarding the endpoint(s)
used was mainly extracted from the clinical studies
section of both the SDP and the SPC. From each
document, the following information was consid-
ered: (i) the product brand name and related
active substance; (ii) specific clinical indica-
tion(s)/disease areas; (iii) primary and non-
primary endpoints; (iv) the authorization date; (v)
approved/rejected status; and (vi) marketing
authorization holder. The relevant data of labora-
tory and clinical endpoints were extracted only
when used as PEs. PROs were included only if they
appeared to be collected in a systematic way from
each subject and through the use of standardized
procedures.
2.4. Data synthesis and statistical analysis
The PEs used here were typically documented as
CROs, LROs and PROs, whilst being classified
according to the Anatomical-Therapeutic-
Chemical (ATC) classification. The PE distribution,
either single or in combination, is herein repre-
sented in Fig. 1. The PROs used were herein cate-
gorized as primary/non-primary endpoints. An
additional analysis of medicinal products using
HRQoL as an endpoint was carried out as well.
Descriptive statistics were used for documenting
the endpoint distribution, with the time-trend of
the use of different endpoints for marketing autho-
rization having been analysed using the v2 test for
trends.3. Results
3.1. Search results
During the study period, a total of 364 medicinal
products had been registered with the EMA for get-
ting a MA approval. Among these, 184 were
excluded because 124 were generics; 49 were
duplicates; 10 had been approved without conduct-
ing clinical studies; and with 1 product the end-
point was not mentioned. Hence, 180 products
were selected for the present analysis and 174
(97%) of them had received proper MA.
3.2. Endpoints
Out of the 180 products here included for the anal-
ysis, LRO were respectively used as PE in 99 (55%),
CRO in 67 (37%), and PRO in 30 (17%) products, as
shown in Fig. 1. The details of primary and non-
PE used in all 180 products are described in
Supplementary Table 1.
3.3. PRO usage
On the whole, PROs as any endpoint had been used
in 82 (46%) products. Among these 82 products,
PROs as PEs were documented in 30 (37%) prod-
ucts; 27 (33%) products used PROs both as primary
and non-primary endpoints. Some 52 (63%) of the
products preferred PROs as non-PEs. Table 1
describes the domains of PROs used as PEs.
Among those 30 products which documented
PROs as PEs, most (18 [60%]) used a list of symp-
toms, followed by HRQoL in 7 (23%) cases. PROs
Table 1 PRO domains used as primary endpoints.
Type of PRO N (%)
Symptoms 18 (60)
Functioning 3 (10)
Health related quality of life 7 (23.3)
Patient global rating 2 (6.7)
388 D. Bansal et al.as PEs were used as the only measurement in 25
(13.9%) products, while in combination with LRO
and CRO in 5 (2.7%) products (Fig. 1). A range of
differences were observed in the level of details
provided on HRQoL and PRO measures in the
EPAR scientific discussion part. PROs were consid-
ered as PEs mainly in specific diseases; for exam-
ple, self-assessment of pain or changes in seizure
frequency. Supplementary Table 2 provides a
detailed description of PROs documented in 82
(46%) cases that used PROs as any endpoint.
Among 82 EPARs, 60 (73%) reported the use of
disease-specific measures, while 45 (55%) used gen-
eric instruments. The Health Survey Short Form-36
(SF-36) and its components were the most fre-
quently (e.g., 19 cases; 23%) used generic instru-
ment. SF-36 was used in combination with either
disease-specific PROs or other HRQoL instruments
in 16 (19%) cases and in isolation in 3 (4%) cases.
The most frequently used disease-specific PROs
included the visual analogue scale for pain (7
cases; 9%).Table 2 Primary endpoint type by Anatomical-Therapeutic-C
ATC class
A – Alimentary tract and metabolism
B – Blood and blood forming organs
C – Cardiovascular system
D – Dermatologicals
G – Genitourinary system and sex hormones
H – Systemic hormonal prep, excluding sex hormones
J – General anti-infectives for systemic use
L – Antineoplastic and immunomodulating agents
M – Musculoskeletal system
N – Nervous system
P – Antiparasitic products
R – Respiratory system
S – Sensory organs
V – Various
Total
PRO: patient reported outcome; ClinRO: clinician reported outcom
one endpoint type is counted more than once in respective endpoi
Number represents the medicinal products registered.3.4. Anatomical-Therapeutic-Chemical
(ATC) classification
PRO usage herein was frequently identified with
antineoplastics, immunomodulators and diseases
of the digestive tract, nervous system, and
genitourinary system (see Table 2). Out of 45
products registered as either antineoplastics or
immunomodulators, 25 (56%) products had used
PROs, but they were used as PEs in only 5 (11%)
cases. All 4 products approved for rheumatoid
arthritis used a well-known composite measure
(including components of PROs, CROs and LROs),
namely the American College of Rheumatology/
ACR 20/50/70 as PE. Among 25 antineoplastic
agents, 12 (48%) products had used PROs as
non-PEs. Formal HRQoL measures herein were
commonly identified, as opposed to more generic
definitions such as signs and symptoms and
improvement. The European Organization for
Research and Treatment of Cancer Quality of Life
Questionnaire Core 30 (EORTC QLQ-C30) was
herein the most frequently used scale for 5 (8%)
products.
Among 18 products registered for nervous sys-
tem disorders, 15 (83%) had used PROs, including
HRQoL. Some 11 (61%) products (3 analgesics, 4
antiepileptics, 1 antipsychotic, 1 antidepressant,
and 2 others) used PROs as PE. All 4 (100%) prod-
ucts registered for seizure disorders used the
patient global assessment of reduction in seizurehemical (ATC) class.
Total PRO ClinRO LRO
N (%) N (%) N (%)
18 6 (33) 2 (11) 10 (56)
14 2 (14) 8 (57) 7 (50)
18 1 (6) 0 (0) 17 (94)
2 0 1 (50) 1 (50)
9 3 (33) 3 (33) 3 (33)
2 0 0 2 (100)
32 0 7 (22) 26 (81)
45 5 (11) 36 (80) 15 (33)
6 1 (17) 3 (50) 3 (50)
18 11 (61) 5 (28) 2 (11)
1 0 0 1 (100)
7 1(14) 0 6 (86)
4 0 1 (25) 3 (75)
4 0 0 4 (100)
180 30 (17) 67 (37) 99 (55)
e; LRO: laboratory reported outcome. Product using more than
nt type.
Table 3 Products exclusively using PRO for evaluation of medicinal product (n = 15).
Product Indication Patient reported outcome
Fosaprepitant Nausea and vomiting Episodes of vomiting or retching recorded on patient
diary cards, FLIE, Patient self assessment of nausea using
VAS, Global satisfaction with the anti-emetic treatment
by VAS, use of rescue therapy
Fluticasone furoate Allergic rhinitis Total Nasal Symptom Score
Recombinant human
C1 inhibitor
Angioedema Time to begin relief at site, Time to Minimal Symptoms,
pain/swelling VAS, Treatment benefit VAS
Fentanyl Breakthrough pain Pain intensity by NRS, Pain relief by Likert Scale, Use of
rescue medication, Global medication performance
assessment
Methylnaltrexone
bromide
Opioid-induced
constipation
Laxation response, Constipation distress scale, Pain
scores, Bowel movement difficulty and frequency, Use of
rescue laxative medication, PGIC, Opioid withdrawal
symptoms using modified Himmelsbach scale
Lacosamide Partial seizures Seizure frequency, QoL in Epilepsy – 31, Health
Outcomes Assessment, Seizure Severity Scale ratings
Fentanyl citrate Breakthrough pain Pain intensity by NRS, global impression-VAS, use rescue
medicine
ChondroCelect* Femoral condylar
Cartilage defects
Overall Knee Injury and Osteoarthritis Outcome Score
Prucalopride Chronic constipation CSBM, Stools consistency and severity of constipation,
Use of laxatives, Patient Assessment of Constipation –
Symptoms and Patient Assessment of Constipation – QoL
questionnaires.
Rilonacept CAPS Key symptom score by Daily Health Assessment Form,
Number of disease-flare days
Milnacipran
Medicament
– VAS scale, PGIC, SF-36-Physical Component Summary,
Fibromyalgia Impact Questionnaire
Fentanyl Breakthrough pain Pain intensity by NRS, Total pain relief (TOTPAR) score,
Patients global assessment, Rescue medication usage.
Conestat alfa Angioedema Time to Beginning of Relief of Symptoms (VAS Score
Decrease of P20 mm with Persistence)
Linaclotide Irritable bowel
syndrome with
constipation
Abdominal Pain, CSBM frequency, SBM frequency, Stool
Consistency, severity and staining, abdominal
discomfort, bloating, QoL (EQ-5D VAS, IBS-QOL, EQ-5D
utility index)
Mirabegron Overactive bladder
syndrome
IEF, Number and mean volume voided of micturition per
24 h, number and level of urgency incontinence
episodes, number of nocturia episodes, mean number of
pads used. Overactive Bladder Questionnaire, WPAI-
Specific Health Problem, Patient Perception of Bladder
Condition, TS-VAS, EQ-5D,, number of physician visits
Qol: Quality of Life; PGIC: Patients Global Impression of Change; SF-36: Short Form-36; IEF: Incontinence Episode Frequency; I-
QOL: Incontinence Quality of Life; PGI-I: Patients Global Impression of Improvement; MTBV: Mean Time between Voids; VAS: Visual
Analogue Scale; FLIE: Functional Living Index-Emesis; IBS: Irritable bowel syndrome; WPAI: Work Productivity and Activity
Impairment; EQ-5D: EuroQol 5 Dimensions Health Questionnaire; NRS: Numeric Rating Scale; VRS: Verbal Rating Scale; CSBM:
complete spontaneous bowel movement; SBM: Spontaneous Bowel Movement; SF-12: Short Form-12; TS-VAS: Treatment satis-
faction-visual analogue scale; CAPS: Cryopyrin-Associated Periodic Syndromes.
* Characterized viable autologous cartilage cells expanded ex vivo expressing specific marker proteins.
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analgesics/4 brands registered during the study
period. During the related clinical trials, the PRO
considered included: the numerical rating scale
(NRS); the Likert scale; and the patient-averaged
summed pain intensity difference (SPID).Conversely, 2 urological products had used PROs
as PEs, e.g., the incontinence episode frequency
and the International Prostate Symptom Score.
Out of the 18 products registered for the digestive
tract during the study period, 9 (50%) used PROs as
any endpoint while 6 (33%) used them as PE. These
Table 4 Medicinal products using health related quality of life scales.
Health related quality of life scale Medicinal products
Functional Assessment of Cancer Therapy and
components
Epoetin theta, Ruxolitinib, Axitinib, Everolimus,
Canakinumab
European Organization for Research and
Treatment of Cancer Quality of Life
Questionnaire and components
Paclitaxel, Degarelix, Everolimus, Pazopanib, Ruxolitinib
EuroQoL/EQ-5D components Teduglutide, Pazopanib, Dexamethasone, Axitinib,
Linaclotide
Short Form-36 and components Certolizumab pegol, Ambrisentan, Olanzapine pamoate,
Eptotermin alfa, Capsaicin, Canakinumab, Milnacipran
Pierre Fabre Medicament, Dexamethasone,
Velaglucerase alfa, Human normal immunoglobulin
(SCIg), Belimumab, Hydrocortisone, Teduglutide,
Degarelix, Tolvaptan, Asenapine maleate, Idebenone,
Eltrombopag
Dermatology Life Quality Index Ustekinumab
Activities of daily living Idebenone
Functional Living Index-Emesis Fosaprepitant
Irritable bowel syndrome – Quality of Life Linaclotide
Work Productivity and Activity Impairment and
components
Mirabegron
Child Health Questionnaire Canakinumab, Velaglucerase alfa, Human normal
immunoglobulin (SCIg)
Health Assessment Questionnaire Certolizumab pegol, Tocilizumab, Golimumab,
Canakinumab
Inflammatory Bowel Disease Questionnaire Certolizumab pegol, Teduglutide
Eastern Cooperative Oncology Group-
performance status scale
Paclitaxel
Quality of Life in Epilepsy – 31 Lacosamide, Eslicarbazepine acetate, Retigabine,
Perampanel
Quality of Life in children with epilepsy Everolimus
Health Outcomes Assessment Lacosamide
Knee injury and Osteoarthritis Outcome Score ChondroCelect (characterized viable autologous
cartilage cells expanded ex vivo expressing specific
marker proteins)
Patient Assessment of Constipation – Quality of
Life
Prucalopride
Fibromyalgia Impact Questionnaire Milnacipran Pierre Fabre Medicament
National Eye Institute Visual Functioning
Questionnaire – 25
Dexamethasone, Aflibercept
Personal Evaluation of Transitions and
Treatments
Asenapine maleate
Quality of Life Enjoyment and Satisfaction
Questionnaire
Asenapine maleate
Subjective Well-being Neuroleptics short form Asenapine maleate
Norfolk Quality of Life – Diabetic Neuropathy Tafamidis
Cystic Fibrosis Questionnaire – Revised Colistimethate sodium
St. Georges Respiratory Questionnaire Glycopyrronium bromide
Overactive Bladder Questionnaire Mirabegron
390 D. Bansal et al.PROs included the levels of spontaneous bowel
movements for assessment of the irritable bowel
syndrome. Similarly, the chemotherapeutic agents
granisetron and palonosetron considered the com-
plete or partial control over nausea and vomiting,
together with patients diaries, as PROs (Tables 3
and 4).3.5. Time-trend of use of endpoints
Fig. 2 displays the usage trends of different PEs
during the study period. Laboratory and device
measurements resulted in being the most typically
used endpoints. The use of all three types of end-
points remained static throughout the study
Fig. 2 Distribution of primary endpoints by year. CRO = clinician reported outcome, PRO = patient reported
outcome, LRO = laboratory endpoints.
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usage by year for LRO (v2value-0.0093, p-0.92),
CRO (v2value-0.279, p-0.60) and PRO (v2 value-
3.179, p-0.07), respectively, were observed.
4. Discussion
This paper has provided a thorough insight into the
PRO usage over a 5-year period post the release of
the EMA reflection paper in 2006. It appeared that
PRO, as any endpoint, had been used for some 82
(46%) products, although as a primary endpoint
was herein considered only for 30 (37%) of them.
Conversely, most products had relied on more
objective (e.g., laboratory or clinical) data.
Overall, these results clearly suggest that PRO
usage, for any endpoint, has increased from 34%
in the study period 1995–2003 to 46% [12].
Although the EMA reflection paper has provided
a range of detailed information relating to the reg-
ulatory expectations for any product to be regis-
tered [20], present data seemed to suggest wide
levels of variation in PRO usage across different
disease areas. The decision to include PROs in
any new product information is a multi-factorial
one. The increasing levels of PRO use in the
industry-sponsored research may be driven by the
need to demonstrate differences among competing
products in terms of health outcomes relative to
expenditures [12,25], but also by the major
United States (2010) health care law Patient
Protection and Affordable Care Act [26] implemen-
tation of the Patient-Centered Outcomes Research
Institute (PCORI). The distribution of PROs, CROs,
and LROs across the range of therapeutic classes
reflects current practices on how the diseases arebeing diagnosed and monitored. Due to the clear
value of patients reports relating to their symp-
toms, it is important that some products, such as
anti-epileptics, analgesics, anti-asthmatics, anti-
allergics and gastrointestinal agents may consis-
tently take PROs into account. Furthermore,
although with agents such as the cardiovascular
and anti-diabetic ones the use of laboratory tests/-
clinical observations may necessarily need to be
considered, the use of PRO measures may better
complement remaining objective endpoints data.
The most typical domain of PRO use in this study
seemed to be the levels of ‘‘symptoms occur-
rence’’, hence confirming previous findings from
both the United States [14] and the European
Union [27]. This dominance of symptom-based
PRO data may be due to the fact that symptoms
are the most important and initial impact of many
diseases as well as treatments. Moreover, patients
can fairly easily quantify the symptoms fre-
quency/severity/duration with the use of simple
scales, such as the visual analogue scales and/or
the patients diaries. Overall, present data showed
as well that many PROs used for obtaining MA are
those which had already been previously validated
(e.g., SF-36, EORTC 30) [28]. From this point of
view, Shah et al. [29] reviewed the prescription
drugs containing the HRQoL terminology approved
in the U.S. analyzing the medicinal products pack-
age inserts (PI) and the summary basis for their
approval. They identified 18 products (mostly used
in oncology), relating to 20 clinical indications,
containing mentions relating to HRQoL improve-
ment levels, with the earliest documented
approved claim having been in 1989. Most of these
products (60%) had used HRQoL measures as non-
392 D. Bansal et al.PEs, and only 1 out of 4 of PI listings used them as
PE. Willke et al. [5] reviewed the PRO endpoints in
product labels of new medicinal products approved
in the U.S. in the time frame 1997–2002. They
found that PROs appeared in 64 (30%) labels, with
the most typical use having been identified with
anti-inflammatory, CNS and gastrointestinal drugs,
with a static usage trend. Gnanasakthy et al. [14]
reviewed the product labels in the time-frame
2006–2010, and found that 28/116 (24%) products
had been authorized with the help of PRO claims.
Discrepancies with data herein presented might
be explained by differences in both sources and
study methods, including: different regulatory
agencies involved; different types of product-
related regulatory documents; and range of thera-
peutic classes reviewed. Indeed, Willke et al. [5]
had analysed a range of U.S. product labels where
the information described, typically based on a
fairly high standard of evidence, can be quoted
on the eventual medicinal product promotion
material. Conversely, the present analysis had
reviewed the EPAR material, which represents a
broader document, including roughly the whole
amount of data which had been generated as part
of the regulatory submission.
Willke et al. had also reported that CROs were
the endpoints most typically used (64% of prod-
ucts) in pre-MA studies, followed by labora-
tory/device endpoints in 50% of cases [5].
Current figures for CROs and LROs were herein
respectively 37% and 55% of products. Another
study [30] focused on the U.S. drug products labels
in the time-frame 2003–2008 identified 36/142
(25.4%) labels with PROs, similar to the figure
(30%) which had been identified in the 1997–2002
time-frame. This apparent consistency of PRO
usage data over time (1997–2008) may be
explained by the fact that the relating PRO EMA
guidance was published in 2006, preceded 4–
5 years earlier by the PRO Harmonization group
efforts. The time-lag between the implementation
of such measures and their increasing levels of
appearance in drug labels may be explained by
the length of most drug development programs.
By 2008, although the final FDA guidance had not
been published yet, arguably better awareness
levels of PRO usage requirements were already
available. Further, Demuro et al. explored the rea-
sons of denial of PRO label claims in the U.S. dur-
ing the time-frame 2006–2010 and found 24/52
(46%) products containing PROs as part of the piv-
otal studies were denied. They found that fit-for-
purpose and study design, data quality, interpreta-
tion, statistical and administrative issues, and lackof demonstrated treatment benefits were the pri-
mary reasons for rejection [31].
Szende et al. [12] reviewed all published EMA
guidance documents, product-level regulatory
documents and the EPAR database between 1995
and 2003 for HRQoL and other PRO measures.
They found that 81 products (34%) included
HRQoL/PRO data, with larger levels (32%) of PRO
usage relating to antineoplastic agents.
Furthermore, Gondek et al. [17] assessed the incor-
poration of HRQoL and symptom assessment in
industry-sponsored cancer clinical trials and
related product labels. They found that out of
2704 industry-sponsored oncology trials, 322 (12%)
had included a PRO measure. Conversely, out of
70 FDA labels, only 6 (9%) PIs included PRO data.
Although their analysis focused on oncology prod-
ucts only, they concluded that the EMA may pre-
sent, during MA procedures, with larger levels of
attention than FDA to HRQoL measures, hence con-
firming other authors suggestions [7]. Similarly,
Rock et al. [32] found that 9 treatment indications
for 7 anticancer therapies had been approved by
the FDA based either on symptom palliation or
improvement in a functional endpoint, represent-
ing 10% of all treatment indications approved dur-
ing the study period (1995–2006). Overall, over
the last decade or so, both the EMA and the FDA
have shown increasing levels of interest towards
PRO usage during MA procedures [20,24]. EMA
appeared, however, to be more flexible and open
to the inclusion of validated and clinically/method-
ologically appropriate PROs [33]. Indeed, many
EMA disease-specific guidelines now require PRO
endpoints to be included as secondary endpoints
(e.g., the Ankylosing Spondylitis Quality of Life;
ASHRQoL) [34]. Furthermore, the EMA has also
issued a Biomarkers Qualification Programme that
provides a better framework for evaluating clinical
trial endpoints, including PROs [35].
The information provided in the EPAR SDPs
reflects only the data which had been considered
during the decision-making procedures; hence,
some of the information submitted for the regula-
tory review may be missing. Therefore, it is possi-
ble that some pharmaceutical companies had
actually included HRQoL measures in their clinical
studies, but only some of these data were
accepted for mention in either the SDP or the pro-
duct label.
Many countries prompt formal agencies, e.g.,
the Health Technology Assessments (HTA) commit-
tees, to specifically assess the relative clinical and
economic benefits of a range of medications. The
HTA committees determine the added benefits of
Role of patient-reported outcomes and other efficacy endpoints 393new technologies for the purpose of reimburse-
ment and pricing decisions and/or for drafting of
clinical guidelines [36,37]. In Europe, the patients
perspectives are typically included in the HTA pro-
cess/decisions [38,39]. For example, patients
organizations are involved in various aspects of
the consultation process of both the German
Institute for Quality and Efficiency in Health Care
(IQWiG) and the United Kingdom National
Institute for Clinical Excellence (NICE) [40]. From
this point of view, NICE has recommended to con-
sider the Dermatology Life Quality Index (DLQI)
scores, whilst assessing the different medications
suitability for the treatment of eczema and
psoriasis [41]. Similarly, the HRQoL patient scoring
on the Adult Growth Hormone Deficiency scale
(HRQoL-AGHDA) has been recommended as one of
the 3 criteria to assess the patient suitability for
the treatment with recombinant human growth
hormone [42].
The importance of PRO consideration has
also been emphasized by the U.S. WellPoint
Foundation (e.g., a charity providing support for
clinical research activities), which has issued a
range of formal advice for drug companies on sub-
mitting data relating to drug cost-effectiveness;
budgetary impact; and assessment of HRQoL
improvement levels [25,43].
Overall, however, there are a number of obsta-
cles possibly limiting the acceptance of PRO
measures by the regulatory agencies. In fact,
according to the FDA [31], the clinical parameters
considered must relate to the clinical indications
and be of sufficient value for the prescribing physi-
cians to justify their inclusion in the product label.
Hence, one could argue that preference would be
given to objective clinical data. Indeed, a number
of PRO measures are relatively new, lacking norma-
tive/validation data [29]. Finally, research spon-
sors may be interested in limiting the number of
endpoints to a critical minimum to improve
chances of obtaining the MA.
It is suggested that there should be an increment
in PRO usage both as primary and non-PE. Those
clinical trials considering the medication benefits
as taken from PRO data as well are likely to have
a far-reaching impact, being possibly able to
attract the attention of stakeholders/patient advo-
cacy groups, which will in turn facilitate access to
new/less affordable treatments [24]. Furthermore,
to improve transparency levels, both regulatory
bodies and industries should ensure complete and
clear reporting of all endpoints used, including
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